Cargando…

Genetic mutation and tumor microbiota determine heterogenicity of tumor immune signature: Evidence from gastric and colorectal synchronous cancers

Both colorectal and gastric cancer are lethal solid-tumor malignancies, leading to the majority of cancer-associated deaths worldwide. Although colorectal cancer (CRC) and gastric cancer (GC) share many similarities, the prognosis and drug response of CRC and GC are different. However, determinants...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Weili, Zhao, Yaxing, Ge, Qiongxiang, Wang, Xiaoli, Jing, Yang, Zhao, Jingwen, Liu, Gang, Huang, He, Cheng, Fei, Wang, Xiaoxi, Ye, Yulin, Song, Wenjing, Liu, Xinjuan, Du, Juan, Sheng, Jianpeng, Cao, Xiaocang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676241/
https://www.ncbi.nlm.nih.gov/pubmed/36420271
http://dx.doi.org/10.3389/fimmu.2022.947080
Descripción
Sumario:Both colorectal and gastric cancer are lethal solid-tumor malignancies, leading to the majority of cancer-associated deaths worldwide. Although colorectal cancer (CRC) and gastric cancer (GC) share many similarities, the prognosis and drug response of CRC and GC are different. However, determinants for such differences have not been elucidated. To avoid genetic background variance, we performed multi-omics analysis, including single-cell RNA sequencing, whole-exome sequencing, and microbiome sequencing, to dissect the tumor immune signature of synchronous primary tumors of GC and CRC. We found that cellular components of juxta-tumoral sites were quite similar, while tumoral cellular components were specific to the tumoral sites. In addition, the mutational landscape and microbiome contributed to the distinct TME cellular components. Overall, we found that different prognoses and drug responses of GC and CRC were mainly due to the distinct TME determined by mutational landscape and microbiome components.